CD19 CAR T

Representative image of a clinical oncology research setting as PeproMene Bio’s PMB-CT01 BAFF-R CAR T data highlight a potential new treatment path for relapsed B-cell lymphoma after CD19 CAR T failure.

Pharma & Biotech

PeproMene Bio’s EHA 2026 data spotlight BAFF-R CAR T in relapsed lymphoma

by Pallavi Madhiraju
May 30, 2026
0 Comments

PeproMene Bio’s PMB-CT01 data raise fresh questions for post-CD19 CAR T lymphoma care. Find out what the early signal means.

Read More

Pharma & Biotech

Citius Oncology tests LYMPHIR before CAR-T therapy in DLBCL. Does immune modulation improve response durability?

by Pallavi Madhiraju
March 5, 2026
0 Comments

Can LYMPHIR boost CAR-T therapy success in lymphoma? Discover what early trial data reveals about immune microenvironment targeting.

Read More